FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016521148> ?p ?o ?g. }

• W2016521148 endingPage "587" @default.
• W2016521148 startingPage "578" @default.
• W2016521148 abstract "The purpose of this study was to investigate the influence of combined inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) and bone morphogenetic protein (BMP) activity in a mixed lytic/blastic prostate cancer lesion in bone. Human prostate cancer cells (C4 2b) were injected into immunocompromised mice using an intratibial injection model to create mixed lytic/blastic lesions. RANK-Fc, a recombinant RANKL antagonist, was injected subcutaneously three times a week (10 mg/kg) to inhibit RANKL and subsequent formation, function and survival of osteoclasts. Inhibition of BMP activity was achieved by transducing prostate cancer cells ex vivo with a retroviral vector expressing noggin (retronoggin; RN). There were three treatment groups (RANK-Fc treatment, RN treatment and combined RN and RANK-Fc treatment) and two control groups (untreated control and empty vector control for the RN treatment group). The progression of bone lesion and tumor growth was evaluated using plain radiographs, hindlimb tumor size, 18F-Fluorodeoxyglucose and 18F-fluoride micro PET-CT, histology and histomorphometry. Treatment with RANK-Fc alone inhibited osteolysis and transformed a mixed lytic/blastic lesion into an osteoblastic phenotype. Treatment with RN alone inhibited the osteoblastic component in a mixed lytic/blastic lesion and resulted in formation of smaller osteolytic bone lesion with smaller soft tissue size. The animals treated with both RN and RANK-Fc demonstrated delayed development of bone lesions, inhibition of osteolysis, small soft tissue tumors and preservation of bone architecture with less tumor induced new bone formation. This study suggests that combined inhibition of the RANKL and the BMP pathway may be an effective biologic therapy to inhibit the progression of established mixed lytic/blastic prostate cancer lesions in bone." @default.
• W2016521148 created "2016-06-24" @default.
• W2016521148 creator A5018649614 @default.
• W2016521148 creator A5039688005 @default.
• W2016521148 creator A5044848608 @default.
• W2016521148 creator A5054681352 @default.
• W2016521148 creator A5064404418 @default.
• W2016521148 creator A5073511028 @default.
• W2016521148 creator A5074622765 @default.
• W2016521148 creator A5077811779 @default.
• W2016521148 date "2011-03-01" @default.
• W2016521148 modified "2023-09-27" @default.
• W2016521148 title "Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion" @default.
• W2016521148 cites W1967615426 @default.
• W2016521148 cites W1973801926 @default.
• W2016521148 cites W1975236830 @default.
• W2016521148 cites W1986275950 @default.
• W2016521148 cites W1986955590 @default.
• W2016521148 cites W1991486724 @default.
• W2016521148 cites W1994001076 @default.
• W2016521148 cites W1995615104 @default.
• W2016521148 cites W1995789564 @default.
• W2016521148 cites W1998024723 @default.
• W2016521148 cites W2002178911 @default.
• W2016521148 cites W2003251793 @default.
• W2016521148 cites W2013953134 @default.
• W2016521148 cites W2015160990 @default.
• W2016521148 cites W2017757468 @default.
• W2016521148 cites W2027835487 @default.
• W2016521148 cites W2030339269 @default.
• W2016521148 cites W2031211482 @default.
• W2016521148 cites W2037325698 @default.
• W2016521148 cites W2039813962 @default.
• W2016521148 cites W2048299560 @default.
• W2016521148 cites W2055195423 @default.
• W2016521148 cites W2055943719 @default.
• W2016521148 cites W2059290265 @default.
• W2016521148 cites W2060529951 @default.
• W2016521148 cites W2060719489 @default.
• W2016521148 cites W2063844097 @default.
• W2016521148 cites W2081417661 @default.
• W2016521148 cites W2087016656 @default.
• W2016521148 cites W2087324367 @default.
• W2016521148 cites W2088982930 @default.
• W2016521148 cites W2102969047 @default.
• W2016521148 cites W2108248718 @default.
• W2016521148 cites W2112523271 @default.
• W2016521148 cites W2113701976 @default.
• W2016521148 cites W2123640548 @default.
• W2016521148 cites W2130687125 @default.
• W2016521148 cites W2137585125 @default.
• W2016521148 cites W2139256061 @default.
• W2016521148 cites W2139996507 @default.
• W2016521148 cites W2141070796 @default.
• W2016521148 cites W2144365339 @default.
• W2016521148 cites W2145269260 @default.
• W2016521148 cites W2158298823 @default.
• W2016521148 cites W2158481098 @default.
• W2016521148 cites W2158734599 @default.
• W2016521148 cites W2164432508 @default.
• W2016521148 cites W2168478740 @default.
• W2016521148 cites W2168772771 @default.
• W2016521148 cites W2293758038 @default.
• W2016521148 cites W2887937198 @default.
• W2016521148 cites W4244095134 @default.
• W2016521148 doi "https://doi.org/10.1016/j.bone.2010.11.003" @default.
• W2016521148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3039095" @default.
• W2016521148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21073986" @default.
• W2016521148 hasPublicationYear "2011" @default.
• W2016521148 type Work @default.
• W2016521148 sameAs 2016521148 @default.
• W2016521148 citedByCount "18" @default.
• W2016521148 countsByYear W20165211482012 @default.
• W2016521148 countsByYear W20165211482013 @default.
• W2016521148 countsByYear W20165211482014 @default.
• W2016521148 countsByYear W20165211482015 @default.
• W2016521148 countsByYear W20165211482016 @default.
• W2016521148 countsByYear W20165211482017 @default.
• W2016521148 countsByYear W20165211482018 @default.
• W2016521148 countsByYear W20165211482022 @default.
• W2016521148 crossrefType "journal-article" @default.
• W2016521148 hasAuthorship W2016521148A5018649614 @default.
• W2016521148 hasAuthorship W2016521148A5039688005 @default.
• W2016521148 hasAuthorship W2016521148A5044848608 @default.
• W2016521148 hasAuthorship W2016521148A5054681352 @default.
• W2016521148 hasAuthorship W2016521148A5064404418 @default.
• W2016521148 hasAuthorship W2016521148A5073511028 @default.
• W2016521148 hasAuthorship W2016521148A5074622765 @default.
• W2016521148 hasAuthorship W2016521148A5077811779 @default.
• W2016521148 hasBestOaLocation W20165211482 @default.
• W2016521148 hasConcept C104317684 @default.
• W2016521148 hasConcept C121608353 @default.
• W2016521148 hasConcept C126322002 @default.
• W2016521148 hasConcept C142724271 @default.
• W2016521148 hasConcept C170493617 @default.
• W2016521148 hasConcept C182615771 @default.
• W2016521148 hasConcept C185592680 @default.
• W2016521148 hasConcept C199343813 @default.

• next